Severe delayed haemolytic anaemia associated with artemether-lumefantrine treatment of malaria in a Japanese traveller

Hasegawa, Chihiro; Kudo, Masaharu; Maruyama, Haruhiko; Kimura, Mikio

doi:10.1016/j.jiac.2017.10.008

Cited by 8 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This scenario is not uncommon as delayed haemolytic anaemia has been reported in other studies with patients receiving ACT treatment. Though the causal relationship between artemether treatment and delayed haemolytic anaemia is yet to be identified (Jarvis et al, 2013;Hasegawa et al, 2018), it is advisable that healthcare professionals should be cautious about the potential of haemolytic complications post treatment.…”

Section: Discussionmentioning

confidence: 99%

Complications of Sub-microscopic Plasmodium vivax Malaria among Orang Asli in Pos Lenjang, Kuala Lipis

Salleh¹,

Rahman²,

Samsusah³

et al. 2021

Trop Biomed

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Complications of Sub-microscopic Plasmodium vivax Malaria among Orang Asli in Pos Lenjang, Kuala Lipis

Salleh¹,

Rahman²,

Samsusah³

et al. 2021

Trop Biomed

View full text Add to dashboard Cite

“…Our study revealed that 28.00% of the participants had artemisinin antibodies in their system. The presence of these drug-induced antibodies has an increased risk of haemolytic anaemia as there are several reports of delayed autoimmune haemolytic anaemia following the administration of artemisinin containing drug [14], [16], [30]- [35]. Although, there are no published data on the prevalence of artemisinin antibodies to compare our findings, the high prevalence observed in this study could be attributed to the WHO guideline for the use of artemisinin as the first line drug for the treatment of malaria and its consequential increased used in hospitals in Nigeria coupled with the poor regulation of use and misuse of antimicrobial agents in Nigeria [10], [22], [25], [29].…”

Section: Discussionmentioning

confidence: 99%

Risk Factors For The Presence Of Artemisinin Antibodies Amongst Patients Undergoing Treatment For Malaria In Benin City, Nigeria

Ogefere

Idemudia

Omoregie

2020

EJMED

View full text Add to dashboard Cite

Artemisinin have being used for the control of malaria worldwide for over a decade and its listing by WHO as the first-line drug for treatment of both severe and uncomplicated malaria and the observed treatment failure have warranted the need to screening malaria patients for the presence of antibodies to malaria. In our locality where there is unregulated use of antimicrobials, the need to ascertain the prevalence of antibodies to artemisinin and evaluate the potential risk factors cannot be overemphasised, hence this study. Blood specimens were collected from 400 randomised patients undergoing treatment for malaria in Benin City, Nigeria. Data on socio-demography were collected with the aid of a well-structured questionnaire. Artemisinin antibodies were detected by drug absorption mechanism (DAM) and immune complex reaction (IMC) methods. ABO, rhesus blood group, and haemoglobin (Hb) phenotype were determined by using standard technique. A total of 112(28.00%) out of the 400 participants had artemisinin antibodies. Gender, marital status, level of education, residential area and living arrangement did not significantly affect the prevalence of artemisinin antibodies whereas age and ethnicity significantly affected the prevalence of artemisinin antibodies (p=0.0244 and 0.0001 respectively). Duration of the last artemisinin used and the mostly used brand of artemisinin as well as the ABO and rhesus blood groups and haemoglobin phenotypes did not significantly affect the production of artemisinin antibodies. Although of all the risk factors age and ethnicity were identified as the only risk factors for the development of artemisinin, we therefore advocate the prudent use of artemisinin-containing antimalarial and concerted efforts in combating self-medication with this drugs to avoid the development of resistance.

show abstract

“…These progressed to kidney failure in 80-90% of cases. The mortality rate was 15-30% (Daubrey-Potey et al, 2004b;Hasegawa et al, 2018;Huggan et al, 2018;Olupot-Olupot, et al, 2017;Sweetman, 2007). There were also rare neurological adverse effects like orofacial dyskinesias observed with amodiaquine in children and adults.…”

Section: Discussionmentioning

confidence: 99%

Analysis of patient information leaflets on Artemisinin-based combination therapy

Daubrey-Potey¹,

Kamagaté²,

Die-Kacou³

2018

Afr. J. Pharm. Pharmacol.

View full text Add to dashboard Cite

The objective of this research was to analyze the various patient information leaflets on Artemisininbased combination therapy (ACTs) sold in Côte-D'Ivoire. A descriptive cross-sectional study was conducted from January 1st to February 20th, 2016, that included all patient information leaflets relating to ACTs registered and marketed in Côte-d'Ivoire. The leaflets were compared to European standards of writing summaries of product characteristics, by focusing particularly on side effects. Regarding artemether-lumefantrine, all leaflets mentioned digestive disorders. As far as endocrine and metabolic systems are concerned, appetite loss and anorexia were outlined in 28.5% and 42.8% of leaflets examined. With regard to skin and annexes, we noticed: rash (100%), pruritus (90%), slate-gray pigmentation (28%) and redness of the face (14%). Finally, only Plasmocid® and Coartem® leaflet reported biological side effects. Regarding artesunate-amodiaquine, side effects involving blood were outlined: agranulocytosis (60%), blood dyscrasia and leucopenia (40%), along with hemolytic anaemia (20%). Side effects affecting gastrointestinal system were nauseas, vomiting and diarrhoea (80%), hepatitis (60%) and fatal hepatitis (20%). Side effects affecting the nervous system include peripheral neuropathy (80%) and extrapyramidal syndrome (20%). Regarding information from pharmaceutical companies differing from one specialty to another for the same molecule, it would be desirable that they harmonize the patient information leaflets contents.

show abstract

Severe delayed haemolytic anaemia associated with artemether-lumefantrine treatment of malaria in a Japanese traveller

Cited by 8 publications

References 20 publications

Complications of Sub-microscopic Plasmodium vivax Malaria among Orang Asli in Pos Lenjang, Kuala Lipis

Complications of Sub-microscopic Plasmodium vivax Malaria among Orang Asli in Pos Lenjang, Kuala Lipis

Risk Factors For The Presence Of Artemisinin Antibodies Amongst Patients Undergoing Treatment For Malaria In Benin City, Nigeria

Analysis of patient information leaflets on Artemisinin-based combination therapy

Contact Info

Product

Resources

About